Thelansis

Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Market Outlook Thelansis’s “Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient shar...

  Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Market Outlook Thelansis’s “Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Overview Extensive-stage small-cell lung cancer (ES-SCLC) is characterized by rapid and widespread growth, making it one of the most lethal forms of cancer. Unlike limited-stage SCLC (LS-SCLC), which has not yet metastasized and can potentially be cured, ES-SCLC is not curable. ES-SCLC is characterized by widesp...

  Jazz Pharmaceuticals plc has announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq®) for maintenance treatment in adults with extensive-stage small cell lung cancer (ES-SCLC). The trial compared the combination therapy to atezolizumab alone following induction therapy with carboplatin, etoposide, and atezolizumab. The Zepzelca and atezolizumab combination showed a statistically significant improvement. Publish Date: 15-10-2024   Source: Jazz Pharmaceuticals plc Extensive-stage small-cell lung cancer (ES-SCLC) is characterized by rapid and widespread growth, making it one of the most lethal forms of cancer. Unlike limited-stage SCLC (LS-SCLC), which has not yet metastasized and can potentially be cured, ES-SCLC is not curable. ES-SCLC is characterized by widespread lung tumor growth, involvement of the other lung, lymph nodes on the opposite side of the ch...

 Extensive-stage small-cell lung cancer (ES-SCLC) is characterized by rapid and widespread growth, making it one of the most lethal forms of cancer. Unlike limited-stage SCLC (LS-SCLC), which has not yet metastasized and can potentially be cured, ES-SCLC is not curable. ES-SCLC is characterized by widespread lung tumor growth, involvement of the other lung, lymph nodes on the opposite side of the chest, or other parts of the body. It may also extend to the fluid surrounding the lungs. Due to its rapid and early metastasis, most individuals with small-cell lung cancer are diagnosed with extensive-stage disease before symptoms become apparent. In most cases, patients diagnosed with ES-SCLC who undergo chemotherapy and prophylactic cranial irradiation still experience persistent intrathoracic disease. The prognosis for ES-SCLC is generally poor, and treatment focuses on providing palliative care. Without chemotherapy, the average survival time is only 8-10 weeks. However, approximatel...